Executive Summary
HHS deployed $337M in stable funding for CDC reagent supply and CMS Medicare appeals processing, affirming long-term commitment to public health infrastructure through 2026-2029. Bullish for for-profit Maximus with $104M firm-fixed revenue and $17.5M runway; neutral for nonprofit ATCC's $233M cost-plus contract with $257M options upside. Cross-pattern: full/open competition favors established vendors in scientific/admin services, signaling sector resilience amid federal budget continuity.
Tracking the trend? Catch up on the prior All HHS Contracts digest from February 27, 2026.
Investment Signals(2)
- Maximus secures steady CMS revenue(HIGH)▲
$104M obligation with $86M outlayed provides reliable cash flow through 2026 for Medicare QIC services.
- ATCC options unlock $257M potential(MEDIUM)▲
Unexercised options beyond $233M obligation could drive growth in CDC reagent services over 10-year term.
Risk Flags(2)
- Execution[MEDIUM RISK]▼
Firm-fixed pricing exposes Maximus to margin squeeze if costs overrun remaining $17.5M.
- Execution[HIGH RISK]▼
10-year ATCC term vulnerable to funding shifts; $62M subawards dilute direct spend.
Opportunities(2)
- ◆
$17.5M unoutlayed balance plus 2026 expiry positions Maximus for extensions in CMS admin consulting.
- ◆
ATCC's $257M options in cost-plus structure offer scalable revenue if exercised for IRR services.
Sector Themes(1)
- ◆
CDC/CMS awards total $337M via open competition for NAICS 5416/541990 services, blending long-duration stability (to 2029) with high outlay execution (>75% disbursed).
Watch List(2)
- 👁
{"entity"=>"Maximus Federal Services, Inc.", "reason"=>"$104M CMS deal nears end-2026 with extension potential amid bullish signal.", "trigger"=>"new awards or outlay completion >$100M"}
- 👁
{"entity"=>"AMERICAN TYPE CULTURE COLLECTION", "reason"=>"Dominant $233M (70% of period value) with $257M options and subaward flows.", "trigger"=>"options exercised or outlays surpassing $200M"}
Get daily alerts with 2 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 2 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC